Poland· PL-100058278
Rifamazid
A rifampicin and isoniazid product containing rifampicinum + isoniazidum, registered in Poland by Tarchomińskie Zakłady Farmaceutyczne "Polfa" S.A.. The same ATC class is registered in 9 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Rifampicin and isoniazid is registered in 9 of 19 countries.
Countries holding a registration under ATC J04AM02 (rifampicin and isoniazid), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 5 of them publish a price we can compare per daily dose
Rifampicin and isoniazid · ATC J04AM02
9 / 19 countries
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
The record
At a glance
URPL (Poland)- Active substance
- Rifampicinum + Isoniazidum
- Manufacturer
- Tarchomińskie Zakłady Farmaceutyczne "Polfa" S.A.
- Country
- Poland (PL)
- ATC code
- J04AM02
- ATC class
- Rifampicin and isoniazid
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
1 priced- gtin05909990086115100 szt.PLN 182.15
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
61 interactions on record for rifampicin and isoniazid.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rifampicin and isoniazid · interactions on record
61 records
61 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Rifampicin and isoniazid in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomRifamazid 150mg/100mg capsulesImported (Poland)
- NorwayRifinahsanofi-aventis (2)
- SwitzerlandRifinah, comprimés enrobésSanofi-Aventis (Suisse) SA
- IrelandRifinah 150/100 mg Film- Coated TabletsSanofi-Aventis Ireland Limited T/A SANOFI
- NetherlandsRifinah 300 mg/150 mg, filmomhulde tabletSanofi B.V.
- SpainRIFINAH 300 MG/150 MG COMPRIMIDOS RECUBIERTOS CON PELÍCULASanofi Aventis S.A.
- SwedenRimactazid 150 mg/75 mg Filmdragerad tablettSandoz A/S
- CzechiaRIFAMPICIN 75MG + ISONIAZID 50MG
Authorised across Europe · EMA
The same active substance is authorised in 17 EEA countries. Names it is sold under:
- Austria · Rifoldin Mit Inh
- Cyprus · Rifamazid
- Denmark · Rimactazid
- Spain · Rifinah
- France · Rifinah
- United Kingdom (Northern Ireland) · Rifinah
- Greece · Rifinah
- Hungary · Rifazid
- Ireland · Rifinah
- Italy · Rifinah
- Lithuania · Rifamazid
- Netherlands · Rifinah
- Norway · Rimactazid
- Portugal · Rifinah
- Romania · Sinerdol Iso
- Sweden · Rimactazid
- Slovenia · Rifinah
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2e11817a-d6ef-4db1-8728-0c800a7c4921 GET /v1/drugs/2e11817a-d6ef-4db1-8728-0c800a7c4921?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsułki twarde",
"source": "urpl",
"strength": "150 mg + 100 mg",
"packaging": "05909990086115 ¦ Rp ¦ 8680\n100 kaps.",
"substance": "Rifampicinum 150 mg + Isoniazidum 100 mg",
"common_name": "Rifampicinum + Isoniazidum",
"pl_product_id": "100058278",
"pozwolenie_nr": "00861",
"auth_procedure": "NAR",
"authorisation_validity": "Bezterminowe"
}See everything about rifampicin and isoniazid.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.